Enliven Therapeutics(US:ELVN)2025-03-13 20:10Financial Performance - Enliven Therapeutics reported a net loss of $23.2 million for Q4 2024, compared to a net loss of $19.4 million in Q4 2023, with a total net loss of $89.0 million for the full year 2024, up from $71.6 million in 2023[9]. - General and administrative (G&A) expenses for Q4 2024 were $6.2 million, compared to $4.8 million in Q4 2023, with full-year G&A expenses increasing to $23.8 million from $19.0 million[9]. - The company reported total operating expenses of $26.9 million for Q4 2024, compared to $22.7 million in Q4 2023, with total operating expenses for the full year reaching $104.6 million, up from $83.5 million[9]. Research and Development - Research and development (R&D) expenses for Q4 2024 were $20.7 million, an increase of 10% from $17.9 million in Q4 2023, while full-year R&D expenses rose to $80.8 million from $64.6 million[9]. - The company plans to report updated Phase 1 data for ELVN-001 in mid-2025 and expects monotherapy and combination data from ELVN-002 Phase 1 trials in the second half of 2025[1]. - Enliven continues to enroll patients in its Phase 1 trial for ELVN-002, targeting HER2+ and HER2 mutant tumors, and plans to report data from these trials in the second half of 2025[9]. Cash Position - As of December 31, 2024, Enliven had cash, cash equivalents, and marketable securities totaling $313.4 million, providing a cash runway into mid-2027[9]. Regulatory and Clinical Updates - Enliven received orphan drug designation from the FDA for ELVN-001 for the treatment of chronic myeloid leukemia (CML)[4]. - The first patient was dosed in the Phase 1 trial evaluating ELVN-001 in Japanese patients with CML[4]. Shareholder Information - Enliven's weighted-average shares outstanding increased to 49.9 million in Q4 2024 from 41.1 million in Q4 2023[13].